N/A N=128 Subacute Low Back Pain in Active Duty
Subacute Low Back Pain
Primary: Lower Back Strength-Extension — 54.5; 50.2; 49.2; 57.5 kg-Force
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=5 Gastric Artery Embolization Trial for Lessening Appetite Nonsurgically
Arterial Embolization · Other Surgical Procedures · Obesity
Primary: Body Weight Average 6 Months Post-Procedure — 237.6 lbs.
N/A N=43 Auto-PAP Therapy For Improved Fetal Growth
Obstructive Sleep Apnea · Pregnancy
Primary: Number of Participants With Slowing of Fetal Growth by 33% or More During the Last Trimester — 8; 8 Participants — p=0.92
N/A N=18 Spinal Cord Stimulation to Augment Activity Based Therapy
Transcutaneous Spinal Stimulation · Walking · Spasticity
Primary: Change in Walking Function - 10m Walk Walking Speed (m/s) — 0.06; 0.16 speed difference in meters per second
N/A N=100 Myopia Assessment of Two Manufacturing Processes
Juvenile Myopia
Primary: Change in Axial Length Progression From Baseline — 0.046; 0.047 mm
Phase 2 N=119 Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Metastatic Squamous Cell Carcinoma of the Hypopharynx · Metastatic Squamous Cell Carcinoma of the Larynx · Metastatic Squamous Cell Carcinoma of the Oral Cavity
Primary: Progression Free Survival (PFS) — 6.08; 4.4 months
Phase 3 N=642 A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug
Psoriatic Arthritis
Primary: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 — 24.1; 56.9; 63.8 percentage of participants — p=<0.0001
N/A N=26 Junctional AV Ablation in CRT-D: JAVA-CRT
Systolic Heart Failure · Atrial Fibrillation (Permanent)
Primary: Number of Patients With Reduction ≥ 15% in Left Ventricular End-systolic Volume (LVESV) — 5; 6 Participants — p=1.00
N/A N=12 Low-Level Laser in Treatment of Head and Neck Lymphedema: A Pilot Study
Head and Neck Cancer · Lymphedema · Fibrosis
Primary: Number of Participants Consented and Enrolled in Study — 12 Participants
Phase 2 N=77 A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis
Cystic Fibrosis
Primary: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) — -0.8; 3.1; 2.7 percentage points
Phase 2 N=166 An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread
Advanced Cancer
Primary: The Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Phase 2 N=145 A Sequenced Behavioral and Medication Intervention for Cocaine Dependence
Cocaine Dependence
Primary: Those Achieving Three Consecutive Weeks of Cocaine Abstinence at the End of the Trial. — 7; 5 Participants
N/A N=28 The Evaluation Of The Efficiency Of Micro-osteoperforation
Crowding of Teeth
Primary: Rate of Mandibular Teeth Alignment — 4.27; 2.82; 2.08; 2.31 millimeter (mm)
Phase 2 N=31 PF-04449913 For Patients With Acute Myeloid Leukemia at High Risk of Relapse After Donor Stem Cell Transplant
Adult Acute Myeloid Leukemia in Remission · Recurrent Adult Acute Myeloid Leukemia
Primary: Relapse-free Survival in Days — 142 days
Phase 3 N=1,705 A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)
Psoriatic Arthritis
Primary: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 — 36.2; 65.0; 70.6; 78.5 percentage of participants — p=<0.0001